Figure 2.
Pre-tumor lysate treatment results in similar survival improvement as compared to dendritic cell therapy in 2 glioma mouse models. Mice were treated with autologous lysate 14 and 7 days before tumor inoculation with 5 × 105 glioma cells. In the GL261 glioma model both (A) intraperitoneal and (B) subcutaneous injection of lysate (n = 16 and n = 10 respectively) were studied in comparison to PBS treatment (n = 9). (C) For the CT2A glioma model only subcutaneous lysate treatment was tested. Moreover, in the two bottom graphs (subcutaneous injection), dendritic cell therapy (n = 6) was performed and applied as a literature based control condition. For graphs (A) and (B) data of two independent experiments were pooled. Statistical significance was calculated by Log-rank test, *p < 0.05.